UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (USD $) In Thousands, except Per Share data, unless otherwise specified	3 Months Ended
	Jul. 31, 2013	Jul. 31, 2012
Operating revenue:
Personalized oncology solutions	$ 622	$ 918
Translational oncology solutions	2,398	1,188
Total operating revenue	3,020	2,106
Costs and operating expenses:
Cost of personalized oncology solutions	793	772
Cost of translational oncology solutions	878	699
Research and development	402	387
Sales and marketing	642	709
General and administrative	1,071	1,138
Total costs and operating expenses	3,786	3,705
Loss from operations	(766)	(1,599)
Other (expense) income:
Change in fair value of warrant liability	(1,462)	285
Other expense	(1)	(6)
Total other (expense) income	(1,463)	279
Loss before provision for income taxes	(2,229)	(1,320)
Provision for income taxes	3	3
Net loss	$ (2,229)	$ (1,323)
Net loss per common share outstanding, including redeemable common stock, basic and diluted (in dollars per share)	$ (0.03)	$ (0.03)
Weighted average common shares outstanding, including redeemable common stock, basic and diluted (in shares)	66,852,100	47,067,000